GRAIL, Inc. (GRAL)
75.09
-0.80
(-1.05%)
USD |
NASDAQ |
Sep 16, 16:00
75.09
0.00 (0.00%)
After-Hours: 17:16
GRAIL Enterprise Value : 2.619B for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 2.619B |
| September 14, 2026 | 2.603B |
| September 11, 2026 | 2.635B |
| September 10, 2026 | 2.694B |
| September 09, 2026 | 2.690B |
| September 08, 2026 | 2.763B |
| September 04, 2026 | 2.818B |
| September 03, 2026 | 2.831B |
| September 02, 2026 | 2.828B |
| September 01, 2026 | 2.794B |
| August 31, 2026 | 2.775B |
| August 28, 2026 | 2.803B |
| August 27, 2026 | 2.915B |
| August 26, 2026 | 2.785B |
| August 25, 2026 | 2.916B |
| August 24, 2026 | 2.650B |
| August 21, 2026 | 2.782B |
| August 20, 2026 | 2.712B |
| August 19, 2026 | 2.533B |
| August 18, 2026 | 2.396B |
| August 17, 2026 | 2.354B |
| August 14, 2026 | 2.261B |
| August 13, 2026 | 2.278B |
| August 12, 2026 | 2.309B |
| August 11, 2026 | 2.601B |
| Date | Value |
|---|---|
| August 10, 2026 | 2.573B |
| August 07, 2026 | 2.333B |
| August 06, 2026 | 2.062B |
| August 05, 2026 | 2.543B |
| August 04, 2026 | 2.477B |
| August 03, 2026 | 2.368B |
| July 31, 2026 | 2.292B |
| July 30, 2026 | 2.407B |
| July 29, 2026 | 2.063B |
| July 28, 2026 | 2.107B |
| July 27, 2026 | 2.212B |
| July 24, 2026 | 2.260B |
| July 23, 2026 | 2.372B |
| July 22, 2026 | 2.386B |
| July 21, 2026 | 2.477B |
| July 20, 2026 | 2.308B |
| July 17, 2026 | 2.473B |
| July 16, 2026 | 2.444B |
| July 15, 2026 | 2.551B |
| July 14, 2026 | 2.496B |
| July 13, 2026 | 2.437B |
| July 10, 2026 | 2.446B |
| July 09, 2026 | 2.615B |
| July 08, 2026 | 2.363B |
| July 07, 2026 | 2.302B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.749B |
| Oncolytics Biotech, Inc. | 93.55M |
| Sangamo Therapeutics, Inc. | 52.77M |
| Sarepta Therapeutics, Inc. | 2.446B |
| Anixa Biosciences, Inc. | 78.07M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -110.25M |
| Revenue (Quarterly) | 44.69M |
| Total Expenses (Quarterly) | 154.93M |
| EPS Diluted (Quarterly) | -2.557 |
| Gross Profit Margin (Quarterly) | -30.61% |
| Profit Margin (Quarterly) | -246.7% |
| Earnings Yield | -12.98% |
| Normalized Earnings Yield | -12.43 |